Two Ivy League Institutions Select 3CLogic Voice AI and Contact Center Solution for ServiceNow to Transform IT Help Desks
Voice AI and cloud contact center solution enables smarter service delivery, automation, real-time insights, and unified ServiceNow experience for academic institutions
ROCKVILLE, Md., June 3, 2025 /CNW/ -- 3CLogic, the leading AI-powered contact center platform purpose-built for ServiceNow®, today announced that two globally recognized academic institutions, both with extensive ServiceNow ITSM deployments, have recently selected it to overcome critical pain points within their IT service desk operations. Both organizations were eager to replace existing solutions, with one operating a legacy on-premise system and the other struggling with limited visibility, fragmented user experiences, and over-reliance on external resources for daily administrative needs.
As digital transformation continues to reshape the landscape of higher education, top-tier universities are turning to 3CLogic to modernize and enhance their IT help desks while maximizing their current and future investments in ServiceNow. By replacing existing systems with a cloud-based Contact Center as a Service (CCaaS) solution designed to complement the Now Platform®, institutions are driving operational efficiency, unified agent experiences, and better support outcomes for faculty, students, and staff.
Unifying ITSM and Voice for a Seamless Experience
Both universities cited the need for a platform based approach in which their voice and contact center needs are woven together with ServiceNow data and workflows, rather than operating alongside them. With the adoption of 3CLogic, agents and service desk managers will benefit from a single pane of glass for incident management, call handling, contact center administration, reporting, and real time decision making, all without leaving ServiceNow.
Driving Autonomy and Rapid Response with AI
Self-service configuration and autonomy were among the key drivers. Each university will leverage 3CLogic's native AI capabilities integrated with ServiceNow, including intelligent voice self-service, call transcription, and speech analytics to improve intelligent call deflection (i.e.: major incident automation, etc.), reduce agent manual tasks (i.e.: call notes, etc.), lower after-hours service costs, and enable independent management of daily service desk operations without needing constant intervention from internal IT or expensive third-party consultants.
Enabling Agents and Empowering Leadership
Leveraging smart voice workflows and identification, each university will be able to seamlessly route critical calls (i.e.: research and medical divisions, etc.) in need of live assistance to the most qualified agents with relevant historical context to enable personalized experiences. Meanwhile, voice and contact center data, once siloed or difficult to correlate, will now integrate with ServiceNow dashboards and Platform Analytics to support data-driven decision-making and deliver immediate value to leadership teams seeking better visibility into service metrics.
These latest selections underscore the growing demand among higher education institutions for a fully integrated approach to IT service management and voice. As the role of technology in education continues to evolve, 3CLogic remains a trusted partner in helping institutions maximize the value of their ServiceNow investments while delivering seamless, AI-powered support experiences. For more information, please contact info@3clogic.com.
About 3CLogic3CLogic transforms customer and employee experiences with its patented and award-winning AI-powered cloud contact center solutions purpose-built to enhance today's leading CRM and Customer Service Management platforms. Globally available and leveraged by the world's leading brands, its offerings empower enterprise organizations with innovative capabilities, such as intelligent self-service, Generative AI, Voice AI, agent automation & coaching, and AI-powered sentiment analytics — all designed to lower operational costs, maximize ROI, and deliver better, faster, and more personalized interactions for IT, employee, and customer service. For more information, please visit www.3clogic.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/two-ivy-league-institutions-select-3clogic-voice-ai-and-contact-center-solution-for-servicenow-to-transform-it-help-desks-302470602.html
SOURCE 3CLogic
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/03/c8694.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Yahoo
2 hours ago
- Yahoo
VSI Leads Groundbreaking National Study Showing Holistic Recovery Program Improves Spine Surgery Outcomes
Study of 50,000+ patients shows Enhanced Surgical Recovery protocol leads to faster healing, reduced opioid use, and fewer re-admissions after spinal fusion surgery RESTON, Va., June 5, 2025 /PRNewswire/ -- Spine surgeons at VSI® have led one of the largest nationwide studies of its kind, revealing that a more comprehensive, patient-centered approach to spine surgery recovery can lead to faster healing, reduced pain, and fewer complications. The research, which analyzed outcomes from more than 50,000 thoracolumbar spinal fusion cases by 1,352 surgeons at 138 centers across the US, validates the effectiveness of an Enhanced Surgical Recovery (ESR) program developed and implemented by VSI's expert team. This research was conducted in collaboration with the HCA Healthcare Spine Research Consortium. "Spine surgery has come a long way, but recovery is where the real transformation happens," explains lead author Dr. Christopher Good, MD, a spine surgeon and the president and CEO of VSI. "With Enhanced Surgical Recovery, we're not just performing successful surgeries; we're empowering patients to heal faster, use less medication, and return to their lives with fewer setbacks. This research proves that when we treat the whole patient, we achieve dramatically better outcomes." A New Standard in Spine Surgery RecoveryThe evidence-based Enhanced Surgical Recovery (ESR) program is a multiphase protocol designed to optimize patient outcomes before, during, and after spinal fusion surgery. It includes pre-surgical education, opioid-sparing anesthesia techniques, and early initiation of mobility and nutrition to accelerate healing and reduce dependence on medications. "This movement is about reimagining what it means to recover from spine surgery," spine surgeon and co-author Dr. Ehsan Jazini says. "We're proving that with the right preparation and post-op care, patients can recover faster, get back to life, and avoid unnecessary complications." Key Findings from the Research Study: Less Pain Medication: Patients in the ESR program used an average of 8 fewer morphine-equivalent milligrams per day. Shorter Hospital Stays: The average patient stay was reduced by nearly half a day (86 hours vs. 98 hours). Fewer Re-admissions: ESR patients had a significantly lower 30-day re-admission rate (5.8% vs. 6.7%), and for single-level surgeries, re-admissions dropped from 5.6% to just 4.2%. About Thoracolumbar Spinal Fusion Surgery:Thoracolumbar spinal fusion is used to stabilize the spine by permanently joining two or more vertebrae in the mid-to-lower back. It is commonly used to treat: Degenerative disc disease Scoliosis Spinal fractures Spondylolisthesis Spinal stenosis Tumors or infections of the spine This surgical procedure can significantly reduce pain, correct spinal deformities, and prevent further deterioration, but recovery is key to long-term success. About VSI:VSI (formerly Virginia Spine Institute), based in Reston, VA, is a nationally recognized leader in spinal healthcare, offering advanced surgical and non-surgical solutions tailored to each patient. With over 30 years of experience and more than 100,000 patients treated, VSI delivers proven outcomes through its personalized, concierge-style approach. For more resources and spine support, listen to the Get Back To Your Life® podcast on iTunes, Spotify, and YouTube. View original content to download multimedia: SOURCE VSI
Yahoo
2 hours ago
- Yahoo
Creative Tech Textile's Seawool® Opens New Horizons for Sustainable Fashion
For World Environment Day, the company is sharing how material innovation can help the global fashion industry meet its sustainability goals. TAINAN, June 5, 2025 /CNW/ -- In celebration of World Environment Day, Creative Tech Textile is sharing the success story behind Seawool® — its innovative material transforming discarded oyster shells and recycled plastic into a sustainable textile solution. This pioneering approach shows how reusing natural waste can move fashion toward a more sustainable future. Fashion's Push to Become More Sustainable The global fashion industry has recently faced growing pressure to become more sustainable. According to the World Economic Forum, incorporating recycled materials into clothing could reduce CO₂ emissions by up to 80%. Yet, polyester—plastic-based and derived from fossil fuels—remains the most widely used fiber in textiles, while less than 1% of clothing materials are recycled into new garments, per the Geneva Environment Network. In particular, there is a growing need to reduce short-lifecycle plastic-based fabrics and increase uptake of circular, low-impact material innovations. Seawool®: The 'Emerald from the Ocean' Creative Tech's proprietary Seawool® material represents a bold leap in sustainable material development. By blending discarded oyster shells from Taiwan with recycled PET plastic bottles, the company has created a textile that is as functional as it is environmentally conscious. Already adopted by leading US apparel brands, Seawool® generates around TWD$200 million (US$6.1 million) in annual revenue and is quickly gaining global traction. In May, Creative Tech showcased Seawool® at PanTextiles Tokyo, an international trade event by the Taiwan Textile Federation. "As consumers grow more conscious of their clothing's environmental impact, we want them to know sustainable material innovations like Seawool® exist and are scalable," noted Eddie Wang, Founder and CEO of Creative Tech Textile. "Our goal is to replace traditional fibers with more environmentally-friendly alternatives — facilitating true sustainability from the upstream end of the fashion industry supply chain." Creative Tech currently produces 2,500 tons of Seawool® annually, repurposing approximately 500 tons of oyster shells. How Seawool® Compares to Traditional Materials Seawool® stands out for both its environmental footprint and fabric properties: Odor-resistant Moisture-wicking Offers UV protection Furthermore, the oyster shell powder inside is a low thermal conductivity material, offering temperature stability. Seawool® also has cost and environmental advantages: 1/10 the cost of down 1/20 the cost of high-grade wool Lower water usage compared to down and wool Performs better for water absorption than polyester Improved odor resistance compared with cotton Comparable thermal regulation to pricier low-conductivity fabrics, but at 1/6 to 1/10 the cost A sustainable world inside an oyster shell While Taiwan produces an estimated 100,000 tons of oyster shells annually, far greater quantities are generated in the US and China, highlighting the abundance of this natural raw material. Turning oyster shells into functional powder requires a specialized process which Creative Tech has mastered with unique production advantages that support large-scale manufacturing. As demand for eco-conscious materials grows, Creative Tech is well-placed to deliver consistent quality and scale for fashion brands seeking sustainable alternatives. About Creative Tech Textile Founded in 2010 and based in Tainan, Taiwan, Creative Tech Textile is a leading innovator in sustainable textiles. Best known for its proprietary, patented Seawool® material—made from discarded oyster shells and recycled PET bottles—the company delivers high-performance fabrics with natural softness, thermal regulation, and odor resistance. As a Bluesign®-certified manufacturer, Creative Tech helps global apparel brands adopt circular, eco-friendly textiles. For more information, visit: View original content to download multimedia: SOURCE Creative Tech Textile View original content to download multimedia:
